BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hoeroldt B, McFarlane E, Dube A, Basumani P, Karajeh M, Campbell MJ, Gleeson D. Long-term outcomes of patients with autoimmune hepatitis managed at a nontransplant center. Gastroenterology. 2011;140:1980-1989. [PMID: 21396370 DOI: 10.1053/j.gastro.2011.02.065] [Cited by in Crossref: 127] [Cited by in F6Publishing: 118] [Article Influence: 11.5] [Reference Citation Analysis]
Number Citing Articles
1 Gleeson D. Long-Term Outcomes of Autoimmune Hepatitis. Clin Liver Dis (Hoboken) 2019;14:24-8. [PMID: 31391933 DOI: 10.1002/cld.797] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
2 Catrysse L, Farhang Ghahremani M, Vereecke L, Youssef SA, Mc Guire C, Sze M, Weber A, Heikenwalder M, de Bruin A, Beyaert R, van Loo G. A20 prevents chronic liver inflammation and cancer by protecting hepatocytes from death. Cell Death Dis 2016;7:e2250. [PMID: 27253414 DOI: 10.1038/cddis.2016.154] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 6.5] [Reference Citation Analysis]
3 Schmeltzer PA, Russo MW. Clinical narrative: autoimmune hepatitis. Am J Gastroenterol 2018;113:951-8. [PMID: 29755125 DOI: 10.1038/s41395-018-0058-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
4 Enomoto H, Nishiguchi S. Similarities and Differences in Autoimmune Hepatitis Epidemiology between East and West: Autoimmune Hepatitis in East Asia, Southeast Asia, and South Asia. Inflamm Intest Dis 2017;1:150-8. [PMID: 29922671 DOI: 10.1159/000454879] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
5 Umemura T, Katsuyama Y, Yoshizawa K, Kimura T, Joshita S, Komatsu M, Matsumoto A, Tanaka E, Ota M. Human leukocyte antigen class II haplotypes affect clinical characteristics and progression of type 1 autoimmune hepatitis in Japan. PLoS One 2014;9:e100565. [PMID: 24956105 DOI: 10.1371/journal.pone.0100565] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
6 Wang G, Tanaka A, Zhao H, Jia J, Ma X, Harada K, Wang FS, Wei L, Wang Q, Sun Y, Hong Y, Rao H, Efe C, Lau G, Payawal D, Gani R, Lindor K, Jafri W, Omata M, Sarin SK. The Asian Pacific Association for the Study of the Liver clinical practice guidance: the diagnosis and management of patients with autoimmune hepatitis. Hepatol Int 2021;15:223-57. [PMID: 33942203 DOI: 10.1007/s12072-021-10170-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
7 Halliday N, Dyson JK, Thorburn D, Lohse AW, Heneghan MA. Review article: experimental therapies in autoimmune hepatitis. Aliment Pharmacol Ther 2020;52:1134-49. [PMID: 32794592 DOI: 10.1111/apt.16035] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
8 Wang Z, Sheng L, Yang Y, Yang F, Xiao X, Hua J, Guo C, Wei Y, Tang R, Miao Q, Zhang J, Li Y, Fang J, Qiu D, Krawitt EL, Bowlus CL, Gershwin ME, Wang Q, Ma X. The Management of Autoimmune Hepatitis Patients with Decompensated Cirrhosis: Real-World Experience and a Comprehensive Review. Clinic Rev Allerg Immunol 2017;52:424-35. [DOI: 10.1007/s12016-016-8583-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
9 Manns MP. Autoimmune hepatitis: the dilemma of rare diseases. Gastroenterology. 2011;140:1874-1876. [PMID: 21524652 DOI: 10.1053/j.gastro.2011.04.026] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.5] [Reference Citation Analysis]
10 Horwich BH, Liang TZ, Dodge JL, Chopra S, Kahn JA, Saito T. Differential IgG4-Producing Plasma Cell Infiltration in Non- and Post-Transplant Plasma Cell Hepatitis. Transpl Int 2022;35:10182. [PMID: 35368647 DOI: 10.3389/ti.2022.10182] [Reference Citation Analysis]
11 Pape S, Schramm C, Gevers TJ. Clinical management of autoimmune hepatitis. United European Gastroenterol J 2019;7:1156-63. [PMID: 31700628 DOI: 10.1177/2050640619872408] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 8.3] [Reference Citation Analysis]
12 Jones D, Manns MP, Terracciano L, Torbenson M, Vierling JM. Unmet needs and new models for future trials in autoimmune hepatitis. The Lancet Gastroenterology & Hepatology 2018;3:363-70. [DOI: 10.1016/s2468-1253(18)30043-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
13 Miyake Y, Yamamoto K, Matsushita H, Abe M, Takahashi A, Umemura T, Tanaka A, Nakamuta M, Nakamoto Y, Ueno Y, Saibara T, Takikawa H, Yoshizawa K, Ohira H, Zeniya M, Onji M, Tsubouchi H; Intractable Hepato-Biliary Disease Study Group of Japan. Multicenter validation study of anti-programmed cell death-1 antibody as a serological marker for type 1 autoimmune hepatitis: Serum anti-PD-1 antibody and type 1 AIH. Hepatol Res 2014;44:1299-307. [DOI: 10.1111/hepr.12305] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
14 Biewenga M, Verhelst X, Baven-Pronk M, Putter H, van den Berg A, Colle I, Schouten J, Sermon F, Van Steenkiste C, van Vlierberghe H, van der Meer A, van Hoek B; Dutch Autoimmune Hepatitis Study Group. Aminotransferases During Treatment Predict Long-Term Survival in Patients With Autoimmune Hepatitis Type 1: A Landmark Analysis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00562-0. [PMID: 34022454 DOI: 10.1016/j.cgh.2021.05.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Fujiwara K, Fukuda Y, Seza K, Saito M, Yasui S, Nakano M, Yokosuka O, Kato N. Long-term observation of acute-onset autoimmune hepatitis presenting clinically and radiologically as acute hepatitis. Hepatol Int 2018;12:191-9. [DOI: 10.1007/s12072-018-9848-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
16 Enweluzo C, Aziz F, Mori A. Comparing efficacy between regimens in the initial treatment of autoimmune hepatitis. J Clin Med Res. 2013;5:281-285. [PMID: 23864917 DOI: 10.4021/jocmr1486w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
17 Schaefer EA, Pratt DS. Autoimmune hepatitis: current challenges in diagnosis and management in a chronic progressive liver disease. Curr Opin Rheumatol 2012;24:84-9. [PMID: 22089102 DOI: 10.1097/BOR.0b013e32834de5d9] [Reference Citation Analysis]
18 Arinaga-hino T, Ide T, Miyajima I, Ogata K, Kuwahara R, Amano K, Kawaguchi T, Nakamura T, Kawaguchi T, Koga H, Yonemoto K, Torimura T; the Kurume Autoimmune Hepatitis Study Group. Risk of malignancies in autoimmune hepatitis type 1 patients with a long-term follow-up in Japan: Malignancies in patients with autoimmune hepatitis in Japan. Hepatol Res 2018;48:E222-31. [DOI: 10.1111/hepr.12973] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
19 Yang F, Wang Q, Bian Z, Ren LL, Jia J, Ma X. Autoimmune hepatitis: East meets west. J Gastroenterol Hepatol. 2015;30:1230-1236. [PMID: 25765710 DOI: 10.1111/jgh.12952] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
20 Katsumi T, Ueno Y. Epidemiology and surveillance of autoimmune hepatitis in Asia. Liver Int 2022. [PMID: 34990076 DOI: 10.1111/liv.15155] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Danielsson Borssén Å, Marschall HU, Bergquist A, Rorsman F, Weiland O, Kechagias S, Nyhlin N, Verbaan H, Nilsson E, Werner M. Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis. Scand J Gastroenterol 2017;52:1022-8. [PMID: 28562110 DOI: 10.1080/00365521.2017.1335772] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
22 Mederacke YS, Kirstein MM, Großhennig A, Marhenke S, Metzler F, Manns MP, Vogel A, Mederacke I. The PNPLA3 rs738409 GG genotype is associated with poorer prognosis in 239 patients with autoimmune hepatitis. Aliment Pharmacol Ther 2020;51:1160-8. [PMID: 32323349 DOI: 10.1111/apt.15722] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
23 Lucey MR, Vierling JM. Clinical presentation and natural history of autoimmune hepatitis. Clin Liver Dis (Hoboken) 2014;3:9-11. [PMID: 30992880 DOI: 10.1002/cld.304] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
24 Chen RL, Wang QX, Ma X. Precision medicine for autoimmune hepatitis. J Dig Dis 2019;20:331-7. [PMID: 31099976 DOI: 10.1111/1751-2980.12786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Jensen MD, Jepsen P, Vilstrup H, Grønbæk L. Increased Cancer Risk in Autoimmune Hepatitis: A Danish Nationwide Cohort Study. Am J Gastroenterol 2021. [PMID: 34622808 DOI: 10.14309/ajg.0000000000001525] [Reference Citation Analysis]
26 Than NN, Ching DK, Hodson J, McDowell P, Mann J, Gupta R, Salazar E, Ngu JH, Oo YH. Difference in clinical presentation, immunology profile and treatment response of type 1 autoimmune hepatitis between United Kingdom and Singapore patients. Hepatol Int 2016;10:673-9. [PMID: 27101826 DOI: 10.1007/s12072-016-9727-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
27 Ngu JH, Gearry RB, Frampton CM, Stedman CA. Predictors of poor outcome in patients w ith autoimmune hepatitis: a population-based study. Hepatology 2013;57:2399-406. [PMID: 23359353 DOI: 10.1002/hep.26290] [Cited by in Crossref: 71] [Cited by in F6Publishing: 62] [Article Influence: 7.9] [Reference Citation Analysis]
28 Thomaides-Brears HB, Lepe R, Banerjee R, Duncker C. Multiparametric MR mapping in clinical decision-making for diffuse liver disease. Abdom Radiol (NY) 2020;45:3507-22. [PMID: 32761254 DOI: 10.1007/s00261-020-02684-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
29 Puustinen L, Boyd S, Mustonen H, Arkkila P, Arola J, Färkkilä M. Prognostic value of clinical variables and liver histology for development of fibrosis and cirrhosis in autoimmune hepatitis. Scandinavian Journal of Gastroenterology 2017;52:321-7. [DOI: 10.1080/00365521.2016.1253768] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
30 Puustinen L, Barner-Rasmussen N, Pukkala E, Färkkilä M. Incidence, prevalence, and causes of death of patients with autoimmune hepatitis: A nationwide register-based cohort study in Finland. Dig Liver Dis 2019;51:1294-9. [PMID: 30850346 DOI: 10.1016/j.dld.2019.01.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
31 Moriya K, Nishimura N, Namisaki T, Takaya H, Sawada Y, Kawaratani H, Kaji K, Shimozato N, Sato S, Furukawa M, Douhara A, Akahane T, Mitoro A, Yamao J, Yoshiji H. Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis. J Clin Med 2021;10:2465. [PMID: 34199421 DOI: 10.3390/jcm10112465] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Yoshizawa K, Matsumoto A, Ichijo T, Umemura T, Joshita S, Komatsu M, Tanaka N, Tanaka E, Ota M, Katsuyama Y, Kiyosawa K, Abe M, Onji M. Long-term outcome of Japanese patients with type 1 autoimmune hepatitis. Hepatology 2012;56:668-76. [PMID: 22334246 DOI: 10.1002/hep.25658] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 7.7] [Reference Citation Analysis]
33 Mells GF, Kaser A, Karlsen TH. Novel insights into autoimmune liver diseases provided by genome-wide association studies. Journal of Autoimmunity 2013;46:41-54. [DOI: 10.1016/j.jaut.2013.07.004] [Cited by in Crossref: 72] [Cited by in F6Publishing: 59] [Article Influence: 8.0] [Reference Citation Analysis]
34 Arndtz K, Shumbayawonda E, Hodson J, Eddowes PJ, Dennis A, Thomaides-Brears H, Mouchti S, Kelly MD, Banerjee R, Neubauer S, Hirschfield GM. Multiparametric Magnetic Resonance Imaging, Autoimmune Hepatitis, and Prediction of Disease Activity. Hepatol Commun 2021;5:1009-20. [PMID: 34141986 DOI: 10.1002/hep4.1687] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Kirstein MM, Metzler F, Geiger E, Heinrich E, Hallensleben M, Manns MP, Vogel A. Prediction of short- and long-term outcome in patients with autoimmune hepatitis. Hepatology 2015;62:1524-35. [PMID: 26178791 DOI: 10.1002/hep.27983] [Cited by in Crossref: 80] [Cited by in F6Publishing: 71] [Article Influence: 11.4] [Reference Citation Analysis]
36 Wang H, Zhao Y, Ren B, Qin Y, Li G, Kong D, Qin H, Hao J, Sun D, Wang H. Endometrial regenerative cells with galectin-9 high-expression attenuate experimental autoimmune hepatitis. Stem Cell Res Ther 2021;12:541. [PMID: 34654474 DOI: 10.1186/s13287-021-02604-2] [Reference Citation Analysis]
37 Trivedi PJ, Hirschfield GM. Review article: overlap syndromes and autoimmune liver disease. Aliment Pharmacol Ther. 2012;36:517-533. [PMID: 22817525 DOI: 10.1111/j.1365-2036.2012.05223.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 65] [Article Influence: 9.3] [Reference Citation Analysis]
38 Grønbæk L, Vilstrup H, Jepsen P. Autoimmune hepatitis in Denmark: Incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. Journal of Hepatology 2014;60:612-7. [DOI: 10.1016/j.jhep.2013.10.020] [Cited by in Crossref: 163] [Cited by in F6Publishing: 140] [Article Influence: 20.4] [Reference Citation Analysis]
39 Gerussi A, Halliday N, Saffioti F, Bernasconi DP, Roccarina D, Marshall A, Thorburn D. Normalization of serum immunoglobulin G levels is associated with improved transplant-free survival in patients with autoimmune hepatitis. Digestive and Liver Disease 2020;52:761-7. [DOI: 10.1016/j.dld.2020.04.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
40 Panayi V, Froud OJ, Vine L, Laurent P, Woolson KL, Hunter JG, Madden RG, Miller C, Palmer J, Harris N. The natural history of autoimmune hepatitis presenting with jaundice. Eur J Gastroenterol Hepatol. 2014;26:640-645. [PMID: 24694760 DOI: 10.1097/meg.0000000000000085] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
41 Takahashi A, Ohira H, Abe K, Miyake Y, Abe M, Yamamoto K, Suzuki Y, Onji M, Tsubouchi H; Intractable Liver and Biliary Diseases Study Group of Japan. Rapid corticosteroid tapering: Important risk factor for type 1 autoimmune hepatitis relapse in Japan. Hepatol Res 2015;45:638-44. [PMID: 25070037 DOI: 10.1111/hepr.12397] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
42 Maruoka R, Aoki N, Kido M, Iwamoto S, Nishiura H, Ikeda A, Chiba T, Watanabe N. Splenectomy prolongs the effects of corticosteroids in mouse models of autoimmune hepatitis. Gastroenterology 2013;145:209-220.e9. [PMID: 23523671 DOI: 10.1053/j.gastro.2013.03.011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
43 Sharma S, Agarwal S, Kaushal K, Anand A, Gunjan D, Yadav R, Saraya A. Presence and type of decompensation affects outcomes in autoimmune hepatitis upon treatment with corticosteroids. JGH Open 2021;5:81-90. [PMID: 33490617 DOI: 10.1002/jgh3.12451] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Czaja AJ. Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis. Dig Dis Sci. 2017;62:2277-2292. [PMID: 28710658 DOI: 10.1007/s10620-017-4675-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 8.0] [Reference Citation Analysis]
45 Faisal N, Renner EL. Recurrence of autoimmune liver diseases after liver transplantation. World J Hepatol 2015;7:2896-905. [PMID: 26689244 DOI: 10.4254/wjh.v7.i29.2896] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Sockalingam S, Blank D, Abdelhamid N, Abbey SE, Hirschfield GM. Identifying opportunities to improve management of autoimmune hepatitis: Evaluation of drug adherence and psychosocial factors. Journal of Hepatology 2012;57:1299-304. [DOI: 10.1016/j.jhep.2012.07.032] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
47 Minghui Z, Kunhua H, Yunwen B, Hongmei L, Jing L, Shaowen W, Longqiaozi S, Chaohui D. Analysis of Differentially Expressed Proteins Involved in Autoimmune Cirrhosis and Normal Serum by iTRAQ Proteomics. Proteomics Clin Appl 2019;13:e1700153. [PMID: 29999587 DOI: 10.1002/prca.201700153] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
48 Ma Y, Su H, Yuksel M, Longhi MS, McPhail MJ, Wang P, Bansal S, Wong GW, Graham J, Yang L, J Thompson R, Doherty DG, Hadzic N, Zen Y, Quaglia A, Heneghan MA, Samyn M, Vergani D, Mieli-Vergani G. Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry. Hepatology 2021;74:2032-46. [PMID: 33971035 DOI: 10.1002/hep.31893] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
49 Ngu JH, Gearry RB, Frampton CM, Stedman CA. Mortality and the risk of malignancy in autoimmune liver diseases: a population-based study in Canterbury, New Zealand. Hepatology 2012;55:522-9. [PMID: 21994151 DOI: 10.1002/hep.24743] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 6.5] [Reference Citation Analysis]
50 Tu H, Chen D, Cai C, Du Q, Lin H, Pan T, Sheng L, Xu Y, Teng T, Tu J, Lin Z, Wang X, Wang R, Xu L, Chen Y. microRNA-143-3p attenuated development of hepatic fibrosis in autoimmune hepatitis through regulation of TAK1 phosphorylation. J Cell Mol Med 2020;24:1256-67. [PMID: 31808606 DOI: 10.1111/jcmm.14750] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
51 Vogelbacher L, Thimme R, Böttler T. [Autoimmune Hepatitis - What is important for clinical practice?]. Dtsch Med Wochenschr 2022;147:470-80. [PMID: 35405751 DOI: 10.1055/a-1520-4214] [Reference Citation Analysis]
52 Sharma R, Verna EC, Söderling J, Roelstraete B, Hagström H, Ludvigsson JF. Increased Mortality Risk in Autoimmune Hepatitis: A Nationwide Population-Based Cohort Study With Histopathology. Clin Gastroenterol Hepatol 2020:S1542-3565(20)31395-1. [PMID: 33065308 DOI: 10.1016/j.cgh.2020.10.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
53 Czaja AJ. Current and prospective pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother. 2014;15:1715-1736. [PMID: 24961409 DOI: 10.1517/14656566.2014.931938] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
54 Nicoll AJ, Roberts SK, Lim R, Mitchell J, Weltman M, George J, Wigg A, Stuart K, Gow P, Macquillan G, Tse E, Levy M, Sood S, Zekry A, Cheng W, Mitchell J, Skoien R, Sievert W, Strasser SI, Mccaughan GW; the ALA Clinical Research Network, Gastroenterological Society of Australia. Beneficial response to mycophenolate mofetil by patients with autoimmune hepatitis who have failed standard therapy, is predicted by older age and lower immunoglobulin G and INR levels. Aliment Pharmacol Ther 2019;49:1314-22. [DOI: 10.1111/apt.15248] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
55 Laschtowitz A, Zachou K, Lygoura V, Pape S, Derben F, Jaeckel E, Oller-Moreno S, Weidemann S, Krech T, Piecha F, Schön G, Liebhoff AM, Al Tarrah M, Heneghan M, Drenth JPH, Dalekos G, Taubert R, Lohse AW, Schramm C. Histological activity despite normal ALT and IgG serum levels in patients with autoimmune hepatitis and cirrhosis. JHEP Rep 2021;3:100321. [PMID: 34381983 DOI: 10.1016/j.jhepr.2021.100321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Sharma R, Verna EC, Simon TG, Söderling J, Hagström H, Green PHR, Ludvigsson JF. Cancer Risk in Patients With Autoimmune Hepatitis: A Nationwide Population-Based Cohort Study With Histopathology. Am J Epidemiol 2022;191:298-319. [PMID: 33913487 DOI: 10.1093/aje/kwab119] [Reference Citation Analysis]
57 Gaber Y, AbdAllah M, Salama A, Sayed M, Abdel Alem S, Nafady S. Metabolic-associated fatty liver disease and autoimmune hepatitis: an overlooked interaction. Expert Rev Gastroenterol Hepatol 2021;:1-9. [PMID: 34263707 DOI: 10.1080/17474124.2021.1952867] [Reference Citation Analysis]
58 Malik N, Venkatesh SK. Imaging of autoimmune hepatitis and overlap syndromes. Abdom Radiol (NY) 2017;42:19-27. [PMID: 27999888 DOI: 10.1007/s00261-016-1019-x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
59 Visseren T, Darwish Murad S. Recurrence of primary sclerosing cholangitis, primary biliary cholangitis and auto-immune hepatitis after liver transplantation. Best Practice & Research Clinical Gastroenterology 2017;31:187-98. [DOI: 10.1016/j.bpg.2017.04.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
60 Corrigan M, Hirschfield GM, Oo YH, Adams DH. Autoimmune hepatitis: an approach to disease understanding and management. Br Med Bull 2015;114:181-91. [DOI: 10.1093/bmb/ldv021] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
61 Baven-Pronk MAMC, Biewenga M, van Silfhout JJ, van den Berg AP, van Buuren HR, Verwer BJ, van Nieuwkerk CMJ, Bouma G, van Hoek B. Role of age in presentation, response to therapy and outcome of autoimmune hepatitis. Clin Transl Gastroenterol. 2018;9:165. [PMID: 29961755 DOI: 10.1038/s41424-018-0028-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
62 Yan M, Yang J, Sun Q, Liu C, Wang Y, Wang W. Hepatocellular carcinoma that arose from primary Sjögren’s syndrome. Annals of Hepatology 2013;12:824-9. [DOI: 10.1016/s1665-2681(19)31327-4] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]
63 Kriese S, Heneghan MA. Current concepts in the diagnosis and management of autoimmune hepatitis. Frontline Gastroenterol 2013;4:2-11. [PMID: 28839695 DOI: 10.1136/flgastro-2012-100208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
64 Ytting H, Larsen FS. Everolimus treatment for patients with autoimmune hepatitis and poor response to standard therapy and drug alternatives in use. Scand J Gastroenterol. 2015;50:1025-1031. [PMID: 25862144 DOI: 10.3109/00365521.2014.998271] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
65 Varyani F, Card T, Kaye P, Aithal GP, West J. The communication of a secondary care diagnosis of autoimmune hepatitis to primary care practitioners: a population-based study. BMC Health Serv Res 2013;13:161. [PMID: 23635009 DOI: 10.1186/1472-6963-13-161] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
66 Czaja AJ. Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis. Aliment Pharmacol Ther. 2014;39:385-406. [PMID: 24387318 DOI: 10.1111/apt.12592] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 6.4] [Reference Citation Analysis]
67 Efe C, Cengiz M, Kahramanoğlu-Aksoy E, Yilmaz B, Özşeker B, Beyazt Y, Tanoğlu A, Purnak T, Kav T, Turhan T, Ozenirler S, Ozaslan E, Wahlin S. Angiotensin-converting enzyme for noninvasive assessment of liver fibrosis in autoimmune hepatitis. Eur J Gastroenterol Hepatol 2015;27:649-54. [PMID: 25860719 DOI: 10.1097/MEG.0000000000000355] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
68 Faisal N, Renner EL. Recurrence of autoimmune liver diseases after liver transplantation. World J Hepatol 2015; 7(29): 2896-2905 [PMID: 26689244 DOI: 10.4254/wjh.v7.i29.2896] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
69 Wang H, Feng X, Yan W, Tian D. Regulatory T Cells in Autoimmune Hepatitis: Unveiling Their Roles in Mouse Models and Patients. Front Immunol 2020;11:575572. [PMID: 33117375 DOI: 10.3389/fimmu.2020.575572] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
70 Dyson JK, Wong LL, Bigirumurame T, Hirschfield GM, Kendrick S, Oo YH, Lohse AW, Heneghan MA, Jones DEJ; UK-AIH Consortium. Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. Aliment Pharmacol Ther 2018;48:951-60. [PMID: 30226274 DOI: 10.1111/apt.14968] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
71 Ducazu O, Degroote H, Geerts A, Hoorens A, Schouten J, Van Vlierberghe H, Verhelst X. Diagnostic and prognostic scoring systems for autoimmune hepatitis: a review. Acta Gastroenterol Belg 2021;84:487-95. [PMID: 34599574 DOI: 10.51821/84.3.014] [Reference Citation Analysis]
72 Peng M, Li Y, Zhang M, Jiang Y, Xu Y, Tian Y, Peng F, Gong G. Clinical features in different age groups of patients with autoimmune hepatitis. Exp Ther Med. 2014;7:145-148. [PMID: 24348780 DOI: 10.3892/etm.2013.1363] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
73 Trivedi PJ, Hirschfield GM. Recent advances in clinical practice: epidemiology of autoimmune liver diseases. Gut 2021;70:1989-2003. [PMID: 34266966 DOI: 10.1136/gutjnl-2020-322362] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]
74 Zhang C, Wu SS, Dong XQ, Wu Z, Zhao H, Wang GQ. The efficacy and safety of different doses of glucocorticoid for autoimmune hepatitis: A systematic review and meta-analysis. Medicine (Baltimore) 2019;98:e18313. [PMID: 31876706 DOI: 10.1097/MD.0000000000018313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Mandorfer M, Simbrunner B. Prevention of First Decompensation in Advanced Chronic Liver Disease. Clin Liver Dis 2021;25:291-310. [PMID: 33838851 DOI: 10.1016/j.cld.2021.01.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 . EASL Clinical Practice Guidelines: Autoimmune hepatitis. Journal of Hepatology 2015;63:971-1004. [DOI: 10.1016/j.jhep.2015.06.030] [Cited by in Crossref: 489] [Cited by in F6Publishing: 395] [Article Influence: 69.9] [Reference Citation Analysis]
77 Wong LL, Fisher HF, Stocken DD, Rice S, Khanna A, Heneghan MA, Oo YH, Mells G, Kendrick S, Dyson JK, Jones DEJ; UK-AIH Consortium. The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility. Hepatology 2018;68:1487-97. [PMID: 29663477 DOI: 10.1002/hep.30031] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
78 Heneghan MA, Yeoman AD, Verma S, Smith AD, Longhi MS. Autoimmune hepatitis. Lancet. 2013;382:1433-1444. [PMID: 23768844 DOI: 10.1016/s0140-6736(12)62163-1] [Cited by in Crossref: 143] [Cited by in F6Publishing: 65] [Article Influence: 15.9] [Reference Citation Analysis]
79 Gordon V, Adhikary R, Appleby V, Das D, Day J, Delahooke T, Dixon S, Elphick D, Hardie C, Hoeroldt B, Hooper P, Hutchinson J, Jones R, Khan F, Aithal GP, Mcgonigle J, Nelson A, Nkhoma A, Pelitari S, Prince M, Prosser A, Sathanarayana V, Savva S, Shah N, Saksena S, Thayalasekaran S, Vani D, Yeoman A, Gleeson D; The UK Multi‐Centre AIH Audit Group. Diagnosis, presentation and initial severity of Autoimmune Hepatitis ( AIH ) in patients attending 28 hospitals in the UK. Liver Int 2018;38:1686-95. [DOI: 10.1111/liv.13724] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
80 Lemoinne S, Heurgue A, Bouzbib C, Hanslik B, Gournay J, Nguyen-Khac E, Bureau C, de Lédinghen V, Ganne-Carrié N, Bourlière M. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF AUTOIMMUNE HEPATITIS. Clin Res Hepatol Gastroenterol 2021;:101772. [PMID: 34332126 DOI: 10.1016/j.clinre.2021.101772] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Hartl J, Ehlken H, Weiler-Normann C, Sebode M, Kreuels B, Pannicke N, Zenouzi R, Glaubke C, Lohse AW, Schramm C. Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. J Hepatol. 2015;62:642-646. [PMID: 25457202 DOI: 10.1016/j.jhep.2014.10.018] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
82 Harnois DM, Yataco ML, Nakhleh RE. Recurrence of autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis after transplantation. Clin Liver Dis (Hoboken) 2014;3:90-2. [PMID: 30992894 DOI: 10.1002/cld.341] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
83 Trivedi PJ, Hirschfield GM. Treatment of autoimmune liver disease: curr ent and future therapeutic options. Ther Adv Chronic Dis. 2013;4:119-141. [PMID: 23634279 DOI: 10.1177/2040622313478646] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
84 Biewenga M, Verhelst XPDMJ, Baven-Pronk MAMC, Putter H, van den Berg AP, van Nieuwkerk KCMJ, van Buuren HR, Bouma G, de Boer YS, Simoen C, Colle I, Schouten J, Sermon F, van Steenkiste C, van Vlierberghe H, van der Meer AJ, Nevens F, van Hoek B; Dutch Autoimmune Hepatitis Study Group. Development and validation of a prognostic score for long-term transplant-free survival in autoimmune hepatitis type 1. United European Gastroenterol J 2021;9:662-71. [PMID: 34165262 DOI: 10.1002/ueg2.12112] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
85 Taubert R, Engel B, Diestelhorst J, Hupa-Breier KL, Behrendt P, Baerlecken NT, Sühs KW, Janik MK, Zachou K, Sebode M, Schramm C, Londoño MC, Habes S, Oo YH, Lalanne C, Pape S, Schubert M, Hust M, Dübel S, Thevis M, Jonigk D, Beimdiek J, Buettner FFR, Drenth JPH, Muratori L, Adams DH, Dyson JK, Renand A, Graupera I, Lohse AW, Dalekos GN, Milkiewicz P, Stangel M, Maasoumy B, Witte T, Wedemeyer H, Manns MP, Jaeckel E; UK-AIH Consortium. Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. Hepatology 2022;75:13-27. [PMID: 34473365 DOI: 10.1002/hep.32134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
86 Roberts SK, Lim R, Strasser S, Nicoll A, Gazzola A, Mitchell J, Siow W, Khoo T, Hamarneh Z, Weltman M, Gow P, Janko N, Tse E, Mishra G, Cheng EH, Levy M, Cheng W, Sood S, Skoien R, Mitchell J, Zekry A, George J, MacQuillan G, Wigg A, Stuart K, Sievert W, McCaughan G; ALA Clinical Research Network. Efficacy and Safety of Mycophenolate Mofetil in Patients With Autoimmune Hepatitis and Suboptimal Outcomes After Standard Therapy. Clin Gastroenterol Hepatol 2018;16:268-77. [PMID: 29050991 DOI: 10.1016/j.cgh.2017.09.063] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
87 Bossen L, Gerussi A, Lygoura V, Mells GF, Carbone M, Invernizzi P. Support of precision medicine through risk-stratification in autoimmune liver diseases – histology, scoring systems, and non-invasive markers. Autoimmunity Reviews 2018;17:854-65. [DOI: 10.1016/j.autrev.2018.02.013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
88 Engel B, Laschtowitz A, Janik MK, Junge N, Baumann U, Milkiewicz P, Taubert R, Sebode M. Genetic aspects of adult and pediatric autoimmune hepatitis: A concise review. Eur J Med Genet 2021;64:104214. [PMID: 33812046 DOI: 10.1016/j.ejmg.2021.104214] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
89 Beisel C, Weiler-Normann C, Teufel A, Lohse AW. Association of autoimmune hepatitis and systemic lupus erythematodes: A case series and review of the literature. World J Gastroenterol 2014; 20(35): 12662-12667 [PMID: 25253972 DOI: 10.3748/wjg.v20.i35.12662] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
90 Czaja AJ. Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis. Dig Dis Sci 2021;66:2493-512. [PMID: 32833154 DOI: 10.1007/s10620-020-06562-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
91 Aljumah AA, Al Jarallah B, Albenmousa A, Al Khathlan A, Al Zanbagi A, Al Quaiz M, Al-Judaibi B, Nabrawi K, Al Hamoudi W, Alghamdi M, Fallatah H. The Saudi association for the study of liver diseases and transplantation clinical practice guidelines for management of autoimmune hepatitis. Saudi J Gastroenterol 2018;24:S1-S20. [PMID: 30264737 DOI: 10.4103/sjg.SJG_159_18] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Dalekos GN, Koskinas J, Papatheodoridis GV. Hellenic Association for the Study of the Liver Clinical Practice Guidelines: Autoimmune hepatitis. Ann Gastroenterol 2019;32:1-23. [PMID: 30598587 DOI: 10.20524/aog.2018.0330] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
93 Palle SK, Naik KB, McCracken CE, Kolachala VL, Romero R, Gupta NA. Racial disparities in presentation and outcomes of paediatric autoimmune hepatitis. Liver Int 2019;39:976-84. [PMID: 30802337 DOI: 10.1111/liv.14081] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
94 Derben FC, Engel B, Zachou K, Hartl J, Hartleben B, Bantel H, Schramm C, Dalekos GN, Manns MP, Jaeckel E, Taubert R. CK-18 cell death markers improve the prediction of histological remission in autoimmune hepatitis during biochemical remission. Liver Int 2021;41:123-7. [PMID: 33043565 DOI: 10.1111/liv.14699] [Reference Citation Analysis]
95 Zaccherini G, Tufoni M, Bernardi M, Caraceni P. Prevention of Cirrhosis Complications: Looking for Potential Disease Modifying Agents. J Clin Med 2021;10:4590. [PMID: 34640608 DOI: 10.3390/jcm10194590] [Reference Citation Analysis]
96 Fujita K, Oura K, Tadokoro T, Nakahara M, Tani J, Morishita A, Kobara H, Tsutsui K, Himoto T, Masaki T. Prognosis of probable autoimmune hepatitis patients: a single-center study in Japan. Intern Emerg Med 2021. [PMID: 33783693 DOI: 10.1007/s11739-021-02720-0] [Reference Citation Analysis]
97 Trivedi PJ, Hubscher SG, Heneghan M, Gleeson D, Hirschfield GM. Grand round: Autoimmune hepatitis. J Hepatol 2019;70:773-84. [PMID: 30465775 DOI: 10.1016/j.jhep.2018.11.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
98 Czaja AJ. Review article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitis. Aliment Pharmacol Ther. 2014;39:1043-1058. [PMID: 24628539 DOI: 10.1111/apt.12701] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
99 Murillo Perez CF, Harms MH, Lindor KD, van Buuren HR, Hirschfield GM, Corpechot C, van der Meer AJ, Feld JJ, Gulamhusein A, Lammers WJ, Ponsioen CY, Carbone M, Mason AL, Mayo MJ, Invernizzi P, Battezzati PM, Floreani A, Lleo A, Nevens F, Kowdley KV, Bruns T, Dalekos GN, Gatselis NK, Thorburn D, Trivedi PJ, Verhelst X, Parés A, Janssen HLA, Hansen BE; GLOBAL PBC Study Group. Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. Am J Gastroenterol 2020;115:1066-74. [PMID: 32618657 DOI: 10.14309/ajg.0000000000000557] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
100 Czaja AJ. Evolving paradigm of treatment for autoimmune hepatitis. Expert Review of Clinical Immunology 2017;13:781-98. [DOI: 10.1080/1744666x.2017.1319764] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 2.4] [Reference Citation Analysis]
101 Bolia R, Rajanayagam J, Hardikar W. Lower 6-MMP/6-TG Ratio May Be a Therapeutic Target in Pediatric Autoimmune Hepatitis. J Pediatr Gastroenterol Nutr 2018;67:695-700. [PMID: 30234756 DOI: 10.1097/MPG.0000000000002146] [Cited by in Crossref: 5] [Article Influence: 1.7] [Reference Citation Analysis]
102 Schmidt T, Schmidt C, Strahl A, Mussawy H, Rolvien T, Jandl NM, Casar C, Oheim R, Schinke T, Lohse AW, Amling M, Schramm C, Barvencik F. A System to Determine Risk of Osteoporosis in Patients With Autoimmune Hepatitis. Clin Gastroenterol Hepatol 2020;18:226-233.e3. [PMID: 31163277 DOI: 10.1016/j.cgh.2019.05.043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
103 Czaja AJ. Challenges in the diagnosis and management of autoimmune hepatitis. Can J Gastroenterol 2013;27:531-9. [PMID: 24078938 DOI: 10.1155/2013/981086] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
104 Grønbaek L, Otete H, Ban L, Crooks C, Card T, Jepsen P, West J. Incidence, prevalence and mortality of autoimmune hepatitis in England 1997-2015. A population-based cohort study. Liver Int 2020;40:1634-44. [PMID: 32304617 DOI: 10.1111/liv.14480] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
105 Dhaliwal HK, Hoeroldt BS, Dube AK, McFarlane E, Underwood JC, Karajeh MA, Gleeson D. Long-Term Prognostic Significance of Persisting Histological Activity Despite Biochemical Remission in Autoimmune Hepatitis. Am J Gastroenterol. 2015;110:993-999. [PMID: 26010310 DOI: 10.1038/ajg.2015.139] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 8.7] [Reference Citation Analysis]
106 Renand A, Habes S, Mosnier JF, Aublé H, Judor JP, Vince N, Hulin P, Nedellec S, Métairie S, Archambeaud I, Brouard S, Gournay J, Conchon S. Immune Alterations in Patients With Type 1 Autoimmune Hepatitis Persist Upon Standard Immunosuppressive Treatment. Hepatol Commun 2018;2:968-81. [PMID: 30094407 DOI: 10.1002/hep4.1202] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
107 van den Brand FF, van der Veen KS, de Boer YS, van Gerven NM, Lissenberg-Witte BI, Beuers U, van Erpecum KJ, van Buuren HR, den Ouden JW, Brouwer JT, Vrolijk JM, Verdonk RC, van Hoek B, Koek GH, Drenth JPH, Guichelaar MMJ, Mulder CJJ, Bloemena E, van Nieuwkerk CMJ, Bouma G; Dutch Autoimmune Hepatitis Study Group. Increased Mortality Among Patients With vs Without Cirrhosis and Autoimmune Hepatitis. Clin Gastroenterol Hepatol. 2019;17:940-947.e2. [PMID: 30291909 DOI: 10.1016/j.cgh.2018.09.046] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
108 Harrison L, Gleeson D. Stopping immunosuppressive treatment in autoimmune hepatitis (AIH): Is it justified (and in whom and when)? Liver Int 2019;39:610-20. [DOI: 10.1111/liv.14051] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
109 Dalekos GN, Arvaniti P, Gatselis NK, Samakidou A, Gabeta S, Rigopoulou E, Koukoulis GK, Zachou K. First Results From a Propensity Matching Trial of Mycophenolate Mofetil vs. Azathioprine in Treatment-Naive AIH Patients. Front Immunol 2021;12:798602. [PMID: 35087524 DOI: 10.3389/fimmu.2021.798602] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Liberal R, Zen Y, Mieli-Vergani G, Vergani D. Liver transplantation and autoimmune liver diseases. Liver Transpl. 2013;19:1065-1077. [PMID: 23873751 DOI: 10.1002/lt.23704] [Cited by in Crossref: 57] [Cited by in F6Publishing: 38] [Article Influence: 6.3] [Reference Citation Analysis]
111 Schramm C, Lohse AW. Autoimmune hepatitis on the rise. Journal of Hepatology 2014;60:478-9. [DOI: 10.1016/j.jhep.2013.11.025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
112 Cole CD, Saxena R. Autoimmune Hepatitis. Surgical Pathology Clinics 2013;6:259-76. [DOI: 10.1016/j.path.2013.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
113 Webb GJ, Rana A, Hodson J, Akhtar MZ, Ferguson JW, Neuberger JM, Vierling JM, Hirschfield GM. Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists. Clinical Gastroenterology and Hepatology 2018;16:278-287.e7. [DOI: 10.1016/j.cgh.2017.09.062] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
114 Jeong SH. Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea. Clin Mol Hepatol 2018;24:10-9. [PMID: 29307132 DOI: 10.3350/cmh.2017.0066] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
115 Rigopoulou EI, Dalekos GN. Current Trends and Characteristics of Hepatocellular Carcinoma in Patients with Autoimmune Liver Diseases. Cancers (Basel) 2021;13:1023. [PMID: 33804480 DOI: 10.3390/cancers13051023] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
116 Richardson N, Ng STH, Wraith DC. Antigen-Specific Immunotherapy for Treatment of Autoimmune Liver Diseases. Front Immunol 2020;11:1586. [PMID: 32793226 DOI: 10.3389/fimmu.2020.01586] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
117 Czaja AJ. Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis. Aliment Pharmacol Ther 2020;51:1286-304. [PMID: 32363674 DOI: 10.1111/apt.15743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
118 Vierling JM, Kerkar N, Czaja AJ, Mack CL, Adams D, Assis DN, Manns MP, Mayo MJ, Nayfeh T, Majzoub AMM, Alzuabi MA, Ding J, Haffar S, Murad MH, Alsawas M. Immunosuppressive Treatment Regimens in Autoimmune Hepatitis: Systematic Reviews and Meta-Analyses Supporting American Association for the Study of Liver Diseases Guidelines. Hepatology 2020;72:753-69. [PMID: 32500593 DOI: 10.1002/hep.31407] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
119 Dyson JK, Webb G, Hirschfield GM, Lohse A, Beuers U, Lindor K, Jones DE. Unmet clinical need in autoimmune liver diseases. J Hepatol. 2015;62:208-218. [PMID: 25234946 DOI: 10.1016/j.jhep.2014.09.010] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
120 Li Y, Yan L, Wang R, Wang Q, You Z, Li B, Zhang J, Huang B, Chen Y, Li Y, Lian M, Tang R, Qiu D, Gershwin ME, Xiao X, Miao Q, Ma X. Serum Immunoglobulin G Levels Predict Biochemical and Histological Remission of Autoimmune Hepatitis Type 1: A Single-Center Experience and Literature Review. Clin Rev Allergy Immunol 2021. [PMID: 33512642 DOI: 10.1007/s12016-021-08833-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Tansel A, Katz LH, El-Serag HB, Thrift AP, Parepally M, Shakhatreh MH, Kanwal F. Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2017; 15: 1207-1217. e4. [PMID: 28215616 DOI: 10.1016/j.cgh.2017.02.006] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 9.6] [Reference Citation Analysis]
122 Purnak T, Efe C, Kav T, Wahlin S, Ozaslan E. Treatment Response and Outcome with Two Different Prednisolone Regimens in Autoimmune Hepatitis. Dig Dis Sci. 2017;62:2900-2907. [PMID: 28871464 DOI: 10.1007/s10620-017-4728-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
123 Torgutalp M, Efe C, Babaoglu H, Kav T. Relationship between serum adenosine deaminase levels and liver histology in autoimmune hepatitis. World J Gastroenterol 2017; 23(21): 3876-3882 [PMID: 28638227 DOI: 10.3748/wjg.v23.i21.3876] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
124 Donaghy L, Barry FJ, Hunter JG, Stableforth W, Murray IA, Palmer J, Bendall RP, Elsharkawy AM, Dalton HR. Clinical and laboratory features and natural history of seronegative hepatitis in a nontransplant centre. Eur J Gastroenterol Hepatol 2013;25:1159-64. [PMID: 23652914 DOI: 10.1097/MEG.0b013e3283610484] [Reference Citation Analysis]
125 Abdollahi M, Khalilian Ekrami N, Ghojazadeh M, Boezen HM, Somi M, Alizadeh BZ. Tacrolimus and mycophenolate mofetil as second-line treatment in autoimmune hepatitis: Is the evidence of sufficient quality to develop recommendations? World J Gastroenterol 2020; 26(38): 5896-5910 [PMID: 33132643 DOI: 10.3748/wjg.v26.i38.5896] [Reference Citation Analysis]
126 Mack CL, Adams D, Assis DN, Kerkar N, Manns MP, Mayo MJ, Vierling JM, Alsawas M, Murad MH, Czaja AJ. Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology 2020;72:671-722. [PMID: 31863477 DOI: 10.1002/hep.31065] [Cited by in Crossref: 200] [Cited by in F6Publishing: 157] [Article Influence: 100.0] [Reference Citation Analysis]
127 Gordon VM, Adhikary R, Aithal GP, Appleby V, Das D, Day J, Delahooke T, Dixon S, Elphick D, Hardie C, Heneghan M, Hoeroldt B, Hooper P, Hutchinson J, Jones RL, Khan F, Metcalf J, Nkhoma A, Pelitari S, Prince M, Prosser A, Saksena S, Sathyanarayana V, Vani D, Yeoman A, Gleeson D. Provision and standards of care for treatment and follow-up of patients with Autoimmune Hepatitis (AIH). Frontline Gastroenterol 2022;13:126-32. [DOI: 10.1136/flgastro-2020-101661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Hartl J, Miquel R, Zachou K, Wong GW, Asghar A, Pape S, Sebode M, Peiseler M, Zenouzi R, Ehlken H, Krech T, Weiler-Normann C, Drenth JPH, Oo YH, Dalekos GN, Heneghan M, Schramm C, Lohse AW. Features and outcome of AIH patients without elevation of IgG. JHEP Rep 2020;2:100094. [PMID: 32280942 DOI: 10.1016/j.jhepr.2020.100094] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
129 Schramm C, Wahl I, Weiler-normann C, Voigt K, Wiegard C, Glaubke C, Brähler E, Löwe B, Lohse AW, Rose M. Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis. Journal of Hepatology 2014;60:618-24. [DOI: 10.1016/j.jhep.2013.10.035] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 6.4] [Reference Citation Analysis]
130 Beyazit Y, Efe C, Tanoglu A, Purnak T, Sayilir A, Taskıran I, Kekilli M, Turhan T, Ozaslan E, Wahlin S. Nitric oxide is a potential mediator of hepatic inflammation and fibrogenesis in autoimmune hepatitis. Scand J Gastroenterol 2015;50:204-10. [PMID: 25495215 DOI: 10.3109/00365521.2014.974203] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]